Belle Healthcare raises tens of millions to build China's leading microsurgery instrument solutions

Recently, Belle Healthcare, a leading brand in China's ophthalmic microsurgical instruments sector, officially announced the completion of a new round of financing totaling tens of millions of yuan. This round was led by Puhua Capital, with Deep Rock Capital participating as a co-investor. X&Q Capital acted as the exclusive financial advisor. The raised funds will be allocated toward the construction of an intelligent manufacturing center for microsurgical instruments, the implementation of ophthalmic smart devices and consumables projects, and the expansion of overseas sales.

Founded in 2017, Belle Healthcare specializes in the research, development, production, and sales of comprehensive series of Class II and III microsurgical instrument kits for ophthalmology and otorhinolaryngology. The founding team was previously the preferred OEM partner in China for a globally leading brand in ophthalmic microsurgical instruments. Entering the stage of independent brand development, Belle Healthcare has gradually established an international R&D team, including experts in ophthalmic surgical consumables from Switzerland and optical device specialists from Germany. This has enabled the accumulation of cross-disciplinary, multidimensional capabilities in product design and development, achieving a transformation toward proprietary intellectual property design.

Through persistent dedication in this highly specialized field, Belle Healthcare's brand "Belle in Focus" has become an influential domestic Chinese brand in ophthalmology. It was selected for the "Belt and Road" Medical Device Overseas Promotion Platform's  2025 Guidelines for the Selection of High-Quality Medical Devices from China and received the 2025 Global Ophthalmic Industry Service Award. Additionally, Belle Healthcare has been recognized as a National High-Tech Enterprise for three consecutive terms.

The microsurgical instrument market represents a highly specialized niche, with ophthalmic microsurgery being particularly precise. It demands solid technical capabilities in micron-level machining, surface finishing, automated assembly, and inspection. Currently, there are few companies in China that focus on this field and maintain continuous investment. Belle Healthcare has gained high recognition from clinical experts in the commercialization of certain segmented products, such as disposable ophthalmic surgical knives and disposable fundus instruments, demonstrating its capability for domestic substitution in China. Belle Healthcare's pipeline of products under development, such as intelligent ophthalmic surgical instruments and equipment, targets a total global market size of approximately 50 billion upon completion of certification. This market is expected to further expand due to aging trends. Belle Healthcare has the potential to become one of the very few Chinese brands capable of competing in the international market.

Belle Healthcare has established a GMP-certified Class 100,000 cleanroom spanning over 5,000 square meters in the Suzhou High-Tech District. The company has invested substantial funds in independently developing an automated production line for micron-level disposable microsurgical instruments. Leading the Chinese medical industry, Belle Healthcare has mastered industrial-grade femtosecond laser processing technology, which represents one of the most advanced intelligent manufacturing equipment technologies globally. This production line was featured in a "Super Production Line" special report by CCTV's Finance Channel in 2023.

With the enhancement of its products and brand influence, Belle Healthcare has established partnerships with several renowned Chinese medical institutions, including Beijing Tongren Hospital, Shanghai Eye, Ear, Nose, and Throat Hospital, Zhongshan Ophthalmic Center, Aier Eye Hospital, Eye Hospital, WMU, Peking University Third Hospital, and West China Hospital of Sichuan University. Its products have received high recognition from clinical experts, leading to rapid growth in its market share in China. Overseas, Belle Healthcare has established sales channels in regions such as Southeast Asia, Europe, and South America, gradually advancing its international expansion.

Looking ahead, Belle Healthcare plans to adopt a model of in-house R&D combined with licensing deals to enhance its pipeline of intelligent surgical equipment and consumables. This will further expand the scope of clinical solutions it can provide, aiming to become a globally leading comprehensive provider of microsurgical instruments. Following its commercial success in ophthalmology, Belle Healthcare intends to horizontally expand its business into other microsurgical fields, such as neurosurgery and otorhinolaryngology, where domestic Chinese brands have yet to achieve full substitution. Belle Healthcare will also continue to build its technological expertise in preparation for future intelligent surgical instrument solutions.